期刊文献+

美国儿童用药立法保障评析及对我国的启示 被引量:16

Analysis of the Legislation on Pediatric Drug Use in US and Its Enlightenment to China
在线阅读 下载PDF
导出
摘要 目的:为促进我国儿童用药相关立法工作的开展、保障儿童用药提供借鉴。方法:介绍并分析美国儿童用药立法历程及现行《最佳儿童药品法》《儿科研究公平法》实施以来对美国儿童用药的影响,提出保障我国儿童用药可及性和安全性的建议。结果与结论:《最佳儿童药品法》中的"6个月的儿科独占保护期"政策激励了药企开展儿科研究的积极性,但是同时影响了其仿制药的上市。《儿科研究公平法》通过强制措施强制药企开展儿科评估,在保障儿童用药安全方面取得了显著的效果,但是对于尚未广泛应用于儿童患者的已上市药品无足够强制力。激励与强制措施并行是促进儿童用药发展的有效途径,建议我国采取修改《处方管理办法》中关于"一品双规"的条款、在保证药品安全性前提下加速相关儿童用药的审批、对相关儿童药品生产企业实行税收优惠政策、推进儿童用药纳入医保报销目录、赋予国家食品药品监督管理总局强制药企开展儿科研究的权力等措施,保障我国儿童用药的可及性和安全性。 OBJECTIVE:To provide reference for promoting the development of related legislation work on ensuring pediatric drug use in China. METHODS:The legislation process of pediatric drug use in US,the effects of current Best Pharmaceuticals for Children Act and Pediatric Research Equity Act on pediatric drug use in US were intrduced and analyzed,suggestions on guarantee-ing the accessibility and safety on pediatric drug use in China were put forward. RESULTS & CONCLUSIONS:The policy"6-month period of pediatric exclusive protection"in Best Pharmaceuticals for Children Act has motivated the enthusiasm of phar-maceutical companies developing pediatric studies,while it affects the marketing of generic drugs. Pediatric Research Equity Act has achieved remarkable effect in terms of ensuring the safety of pediatric drug use by forcing pharmaceutical companies to carry out pediatrics assessments,while there is no enough force for the marketed drugs that has not been widely used for children. En-couragement and enforcement are useful methods for promoting development of pediatric drug use. It is suggested to take measures like modifing"one drug two forms"in Prescription Management Regulations,accelerating approvals of related pediatric drugs on the premise that safety is guaranteed,implementing tax preference for related pharmaceutical companies that produced pediatric drugs,promoting the entry of drug reimbursement list and empowering CFDA to force pharmaceutical companies to implement pedi-atric studies to promote the accessibility and safety of pediatric drugs.
出处 《中国药房》 CAS 北大核心 2017年第13期1740-1743,共4页 China Pharmacy
基金 教育部哲学社会科学研究重大课题攻关项目(No.14JZD025)
关键词 最佳儿童药品法 儿科研究公平法 儿童用药 立法 Best Pharmaceuticals for Children Act Pediatric Research Equity Act Pediatric drug use Legislation
  • 相关文献

参考文献3

二级参考文献37

  • 1李保成.小儿药物部份规格急需改进[J].儿科药学杂志,2005,11(4):63-63. 被引量:1
  • 2国家食品药品监督管理局.药物临床试验机构认定公告[EB/OL].http://www.sda.gov.cn/WS01/CL0069/,2010-01-22.2010-04-22.
  • 3食品药品安全网.儿童用药研发难制约临床应用[EB/OL].(2012-06-12)[2012-10-15].http://www.yybnet.com/www/news/19/96502.html.
  • 4人民网.中国90%药品无儿童剂型政协建议实行政府补贴[EB/OL].(2012-09-20)[2012-10-21].http://health.people.com.cn/n/2012/0920/c14739-19056731.html.
  • 5中国政协新闻网.儿童用药不能再是“掰掰碾碾”[EB/OL].(2012-10-10)[2012-10-20].http://cppcc.people.com.cn/n/2012/1010/c34948-19215005.html.
  • 6新华网.“全国合理用药监测网”露雏形,布点960家医院[EB/OL].(2010-10-21)[2013-04-19].http://news.xinhuanet.com/health/2010-10/21/c_12685842.htm.
  • 7JPMA.Pharmaceutical administration and regulations in Japan2012[EB/OL].(2012-03)[2012-09-16].http://www.jpma.or.jp/english/parj/1003.html.
  • 8Hoppu K,Anabwani G,Garcia-Bournissen F,et al.The status of paediatric medicinesinitiatives around the world:what has happened and what has not?[J].Eur J Clin Pharmacol,2012,68(1):1.
  • 9Hidefumi N,Masahiro O.Facilitation of paediatric research in Japan[M].Tokyo:Karger Publishers,2010:1522.
  • 10Beckloff Associates.Pediatric exclusivity and drug development requirements in the overall pediatric population[EB/OL].(2009-08-05)[2012-09-16].http://cardinalhealth.com/beckloff/documents/pdf/PEDIATRIC%20EXCLUSIVITY090209.

共引文献54

同被引文献158

引证文献16

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部